期刊文献+

林胜友主任中医师治疗化疗相关性呕吐经验 被引量:5

Chief TCM Doctor LIN Shengyou's Experience in Treating Chemotherapy-associated Vomiting
下载PDF
导出
摘要 [目的]分析讨论林胜友主任中医师治疗化疗相关性呕吐的临证经验。[方法]通过跟师学习,归纳整理病案,结合林师平日指导,分析化疗相关性呕吐的病因病机,总结林师治疗该疾病的临床经验,并附验案加以佐证。[结果]林师认为化疗相关性呕吐的病因病机为中焦土虚,胃气失和;腑实不通,浊气犯胃;肝胆不利,气机失转,治疗上主要从健脾土、通肠腑、畅气机着手。所举验案,患者辨证为脾虚腑实,兼有肝郁,采取健脾通腑,辅以疏肝解郁治疗化疗相关性呕吐,疗效明显,顺利帮助患者度过化疗阶段。[结论]林师治疗化疗相关性呕吐采用健脾、通腑、疏肝治法,通补并用,可以取得较好的疗效。 [Objective]To analyze and discuss Chief traditioral Chinese medicine(TCM)Doctor LIN Shengyou's clinical experience in treating chemotherapy-associated vomiting.[Methods]Through learning from teacher,summarizing and sorting out the medical records,combined with the daily guidance of Teacher LIN,the etiology and pathogenesis of chemotherapy-related vomiting were analyzed,the clinical experience of Teacher LIN in treating this disease was summarized,and one case was presented as proof.[Results]Teacher LIN thinks that the etiology and pathogenesis of chemotherapy-related vomiting are deficiency in middle-Jiao and disharmony in stomach;the excessive bowels are impassable,the pathogenic factors invade the stomach;the liver and gallbladder are unfavourable,and the moveonert of Qi is abnormal.The treatments mainly focus on tonifying the spleen,stretching the bowels and Qi movement.In the medical case,the patient was differentiated as spleen deficiency,the impassable bowels,and liver depression,the treatment of strengthening the spleen and dredging the viscera,combined with soothing the liver and relieving depression was adopted,the patient achieved obvious curative effect,and successfully completed the chemotherapy stage.[Conclusion]Teacher LIN treats chemotherapyrelated vomiting with strengthening the spleen,dredging the bowell and soothing the liver,combined dredging with tonifying,and achieves good curative effects.
作者 沈一炜 姜静 陈帅 林胜友 SHEN Yiwei;JIANG Jing;CHEN Shuai(The Fourth Clinical Medical College of Zhejiang Chinese Medical University,Hangzhou,310053,China;The Third Clinical Medical College of Zhejiang Chinese Medical University)
出处 《浙江中医药大学学报》 CAS 2020年第11期1099-1101,1123,共4页 Journal of Zhejiang Chinese Medical University
关键词 肿瘤 化疗 恶心呕吐 健脾 通肠腑 疏肝 名医经验 林胜友 tumor chemotherapy nausea and vomiting strengthening the spleen dredging the bowell soothing the liver experience of famous doctor LIN Shengyou
  • 相关文献

参考文献5

二级参考文献41

  • 1孙燕.肿瘤药物治疗百年回顾与展望[J].中华肿瘤杂志,2004,26(11):701-703. 被引量:16
  • 2刘长波.阳(气)虚火动病机浅说[J].广州中医学院学报,1995,12(3):43-45. 被引量:8
  • 3王玉杰.苦燥伤阴商榷[J].中华中医药杂志,2006,21(2):95-96. 被引量:2
  • 4岳广欣,黄启福,陈家旭,贾春华.相火在抑郁症发病过程中的地位和作用[J].中医研究,2007,20(2):1-4. 被引量:27
  • 5Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-ceU lung cancer: results of the NCIC CTG BR19 study.J Clin Oncol, 2013, 31 (27): 3320-3326.
  • 6Kelly K, Altorki N, Eberhardt W, et al. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.J Clin Oncol, 2014, 32: abstr 7501.
  • 7Pennell NA, NeaI JW, chart JE, et al. SELECT: a multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. ASCO Annual Meeting Proceedings, 2014, 32( 15_suppl): 7514.
  • 8Ready N, Janne PA, Bogart J, et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.J Thorac Oncolj 2010, 5(9): 1382-1390.
  • 9Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S00Z3. J Clin Oncol, 2008, 26(15): 2450-24S6.
  • 10Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small- cell lung cancer (OPTIMAL, CTONG-080Z): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.

共引文献161

同被引文献92

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部